Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma

Summary

The purpose of the study is to comply with the Pediatric Investigation Plan requirements of Ipilimumab

Timeline

Start

2012-11-12

Primary completion

2016-07-31

Completion

2016-07-31

Outcome

Outcome not reported

Stopped (Enrollment): “Slow accrual”

Publications

• Geoerger B, Bergeron C, Gore L, Sender L, Dunkel IJ, Herzog C, Brochez L, Cruz O, Nysom K, Berghorn E, Simsek B, Shen J, Pappo A. Phase II study of ipilimumab in adolescents with unresectable stage III or IV malignant melanoma. Eur J Cancer. 2017 Nov;86:358-363. doi: 10.1016/j.ejca.2017.09.032. Epub 2017 Nov 5.

Drugs

Indications